Showing 1 - 5 results of 5 for search 'Amnon Amit', query time: 0.03s Refine Results
  1. 1
    Vulvar Cancer in the North of Israel

    Vulvar Cancer in the North of Israel by Orit Kaidar-Person, Nour Ibrahim, Amnon Amit, Roxolyana Bortnyak-Abdah

    Published 2014-07-01
    Get full text
    Article
  2. 2
    [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients

    [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients by Ronit Gill, Roxolyana Abdah-Bortnyak, Amnon Amit, Uval Bar-Peled, Zohar Keidar

    Published 2022-09-01
    Get full text
    Article
  3. 3
    Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?

    Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)? by Amnon Amit, Edmond Sabo, Avielle Movsas, Yamit Efrat-Tamam, Ari Reiss, Emad Matanes, Geula Klorin

    Published 2019-01-01
    Get full text
    Article
  4. 4
    Does sentinel lymph node biopsy in endometrial cancer surgery have an impact on the rate of adjuvant post operative pelvic radiation? An Israeli Gynecologic Oncology Group Study

    Does sentinel lymph node biopsy in endometrial cancer surgery have an impact on the rate of adjuvant post operative pelvic radiation? An Israeli Gynecologic Oncology Group Study by Yoav Brezinov, Tamar Katzir, Ofer Gemer, Limor Helpman, Ram Eitan, Zvi Vaknin, Tally Levy, Amnon Amit, Ilan Bruchim, Inbar Ben Shachar, Ilan Atlas, Ofer Lavie, Alon Ben-Arie

    Published 2022-06-01
    Get full text
    Article
  5. 5
    Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA tr... by Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven, Elena I. Braicu, Amnon Amit, Andrés Redondo, Ruchit Shah, Nehemiah Kebede, Carol Hawkes, Divya Gupta, Tatia Woodward, David M. O’Malley, Antonio González-Martín

    Published 2022-09-01
    Get full text
    Article

Search Tools: